Cogent Biosciences, Inc.
COGT
$11.40
-$0.02-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.35% | 25.91% | 28.97% | 32.26% | 34.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.91% | 32.58% | 34.49% | 43.13% | 42.36% |
| Operating Income | -26.91% | -32.58% | -34.49% | -43.13% | -42.36% |
| Income Before Tax | -27.02% | -32.98% | -36.38% | -44.30% | -43.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.02% | -32.98% | -36.38% | -44.30% | -43.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.02% | -32.98% | -36.38% | -44.30% | -43.17% |
| EBIT | -26.91% | -32.58% | -34.49% | -43.13% | -42.36% |
| EBITDA | -27.13% | -32.85% | -34.69% | -43.22% | -42.06% |
| EPS Basic | 99.66% | -29,898.61% | -30,730.15% | -32,674.43% | -31,011.92% |
| Normalized Basic EPS | 99.66% | -30,022.50% | -30,815.87% | -32,770.16% | -31,098.14% |
| EPS Diluted | 99.66% | -29,898.61% | -30,730.15% | -32,674.43% | -31,011.92% |
| Normalized Diluted EPS | 99.66% | -30,022.50% | -30,815.87% | -32,770.16% | -31,098.14% |
| Average Basic Shares Outstanding | 75.29% | 0.80% | -1.96% | -4.67% | -4.79% |
| Average Diluted Shares Outstanding | 75.29% | 0.80% | -1.96% | -4.67% | -4.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |